What happens in the seconds before a high-stakes penalty is not simply a test of courage, willpower or preparation.

Swedish Orphan Biovitrum AB (publ) (Sobi) (STO:SOBI) is pleased to announce that Canada's Drug Agency (CDA) has issued a positive reimbursement recommendation ...

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) is pleased to announce that Canada’s Drug Agency (CDA) has issued a positive reimbursement recommendation with conditions for PrEMPAVELI ® ...

The company provides branded streaming app technology for PBS member stations across connected TVs, mobile devices and the ...

Scientists are getting closer to figuring out how amyloid immunotherapy causes ARIA, and perhaps how to prevent it. At last month’s AD/PD conference in Copenhagen, Denmark, the spotlight was on innate ...

Complement component 3, often called C3, is an essential protein of the immune system. This protein plays a vital role in the body’s innate immune system, providing the first line of defense against ...

Quantum computers—devices that process information using quantum mechanical effects—have long been expected to outperform classical systems on certain tasks. Over the past few decades, researchers ...

UTC approves a settlement for Cascade to pay up to $2 million after deadly 2023 LNG fire. Investigation finds failures in equipment securing, contractor oversight and more. Settlement mandates ...

Bi-Mart announced Jan. 27 the company will close its five Cascade Farm and Outdoor locations this spring to focus on Bi-Mart’s expansion efforts in the Pacific Northwest. According to a press release, ...

C3G and IgAN are both rare forms of chronic kidney disease affecting the glomeruli, the kidney’s blood filters, but they arise from different immune system issues. Both conditions are immune-mediated ...

Scientists have spotted a new variety of riled-up microglia that drives swelling in the human brain. In the November 18 Neuron, researchers from China led by Haixiao Liu, Shunnan Ge, and Yan Qu at ...

Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...